Trials / NCT03184584
Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Terminated Phase 2 / Phase 3 Drug / neuroprotection
Why it stopped: Terminated early due to redeployment of study site staff during Covid-19 pandemic
- Sponsor
- Liminal BioSciences Ltd.
- Treatment
- PBI-4050
- Gene
- Not stated
- Conditions
- Alström Syndrome
- Ages
- 16 Years to no upper limit
- Enrollment
- 10 participants
- Started
- 2017-10-09
- Main results expected
- 2020-05-08
- Results posted
- Not yet
- Record last updated
- 2020-11-03
What the study is testing
Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.
Where it runs
United Kingdom (1)
- University Hospitals Birmingham NHS Foundation Trus, Birmingham